Synergistic Anticancer Activity of Cannabinoids and Terpenes Against Triple-Negative Breast Cancer Resistance
International Journal of Molecular Sciences · 17.03.2026 · 27 (6) · 2730
DOI: 10.3390/ijms27062730 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.03.2026. Verfasst von Mounika Aare und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Cannabinoids, Drug Resistance, Neoplasm, Terpenes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Florida Cancer innovation, Department of Health, Florida, Florida Cancer Innovation Fund from the Department of Health, Florida.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) remains highly aggressive and refractory to conventional treatments, underscoring the need for novel combination strategies. Here, we employed 2D and 3D in vitro models, transcriptomic profiling, and in vivo xenograft studies to evaluate the anticancer efficacy of cannabinoids combined with the terpene β-caryophyllene (BC) in resistant TNBC models. Among the tested cannabinoids, cannabichromene (CBC) exhibited the greatest potency, and its combination with BC at sub-toxic concentrations significantly reduced IC50 values, enhanced cytotoxicity in spheroids, and suppressed colony formation and migration. The combination treatment induced pronounced G1 cell cycle arrest and increased apoptotic cell death. Western blot analyses revealed downregulation of PARP, Survivin, mTOR, Vimentin, Glypican-5, and PD-L1, while RNA sequencing demonstrated suppression of proliferative and migratory signaling pathways alongside activation of apoptosis, autophagy, and ferroptosis-related pathways. In vivo, CBC + BC significantly inhibited tumor growth in MDA-MB-231 xenografts, outperforming single-agent treatments. Collectively, these findings demonstrate that BC synergistically enhances cannabinoid activity, yielding superior antiproliferative and anti-migratory effects, and highlight this combination as a promising therapeutic strategy for resistant TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA.
- Cancer Biology Department, Mayo Clinic, Jacksonville, FL 32224, USA.
ORCID-Profile: Mounika Aare, Aakash Nathani, Mandip Singh
Förderung
- Florida Cancer innovation, Department of Health, Florida
- Florida Cancer Innovation Fund from the Department of Health, Florida
Zitieren
APA
Aare, M., Lazarte, J. M., Nathani, A., Boirie, B., Turley, T. N., Copland, J. A., & Singh, M. (2026). Synergistic Anticancer Activity of Cannabinoids and Terpenes Against Triple-Negative Breast Cancer Resistance. International Journal of Molecular Sciences, 27(6), 2730. https://doi.org/10.3390/ijms27062730
Vancouver
Aare M, Lazarte JM, Nathani A, Boirie B, Turley TN, Copland JA, et al. Synergistic Anticancer Activity of Cannabinoids and Terpenes Against Triple-Negative Breast Cancer Resistance. International Journal of Molecular Sciences. 2026;27(6):2730. doi:10.3390/ijms27062730
BibTeX
@article{Aare2026,
author = {Aare, Mounika and Lazarte, Jassy Mary and Nathani, Aakash and Boirie, Breana and Turley, Tamiel N and Copland, John A and Singh, Mandip},
title = {Synergistic Anticancer Activity of Cannabinoids and Terpenes Against Triple-Negative Breast Cancer Resistance},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2730},
doi = {10.3390/ijms27062730}
}
EUVIMED